Opus Genetics, Inc. Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants
Opus Genetics, Inc. (IRD) reported Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants of 15.90 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants · last filed 2026-08-06
- Opus Genetics, Inc. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2026-06-30 was 15.90M shares.
- Opus Genetics, Inc. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2025-06-30 was 0.00 shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 3 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 6 month |
|---|---|---|
| 2026-06-30 | 15.90M shares 10-Q · filed 2026-08-06 | 0.00 shares 10-Q · filed 2026-08-06 |
| 2025-06-30 | 0.00 shares 10-Q · filed 2026-08-06 | 0.00 shares 10-Q · filed 2026-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |